

General information about company		
Scrip code*	543616	
NSE Symbol*	NOTLISTED	
MSEI Symbol*	NOTLISTED	
ISIN*	INE0MKA01014	
Name of company	TRIDENT LIFELINE LIMITED	
Type of company	SME	
Class of security	Equity	
Date of start of financial year	01-04-2025	
Date of end of financial year	31-03-2026	
Date of board meeting when results were approved	07-05-2026	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	29-04-2026	
Description of presentation currency	INR	
Level of rounding	Lakhs	
Reporting Type	Half Yearly	
Reporting Quarter	Yearly	
Nature of report standalone or consolidated	Standalone	
Whether results are audited or unaudited for the quarter ended	Audited	
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited	
Segment Reporting	Single segment	
Description of single segment	Pharmaceutical	
Start date and time of board meeting	07-05-2026 17:00	
End date and time of board meeting	07-05-2026 18:15	
Whether cash flow statement is applicable on company	Yes	
Type of cash flow statement	Cash Flow Indirect	
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion	
Whether the company has any related party?	Yes	
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes	
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA	
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA	
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No	
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?		
(b) If answer to above question is No, please explain the reason for not complying.		
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes	
Latest Date on which RPT policy is updated	07-05-2026	
Indicate Company website link for updated RPT policy of the Company	https://www.tridentlifeline.com/	
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	Yes	
No. of times funds raised during the quarter	2	
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	NA

Financial Results – Other than Bank				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period		01-10-2025	01-04-2025	
Date of end of reporting period		31-03-2026	31-03-2026	
Whether results are audited or unaudited		Audited	Audited	
Nature of report standalone or consolidated		Standalone	Standalone	
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.			
1	Revenue From Operations			
	Revenue from operations	5564.1	10189.95	
	Other income	252.77	417.09	
	Total Income	5816.87	10607.04	
2	Expenses			
(a)	Cost of materials consumed	2777.89	5538.16	
(b)	Purchases of stock-in-trade	770.96	885.21	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	49.71	-195.06	
(d)	Employee benefit expense	200.74	381.14	
(e)	Finance costs	91.89	166.25	
(f)	Depreciation and amortisation expense	75.38	185.93	
(g)	Other Expenses			
1	Other Expenses	462.84	1147.51	
	Total other expenses	462.84	1147.51	
	Total expenses	4429.41	8109.14	
3	Profit before exceptional and extraordinary items and tax	1387.46	2497.9	
4	Exceptional items	0	0	
5	Profit before extraordinary items and tax	1387.46	2497.9	
6	Extraordinary items	0	0	
7	Profit before tax	1387.46	2497.9	
8	Tax Expense			
	Current tax	371.31	640.06	
	Deferred tax	48.59	48.59	
	Total tax expenses	419.9	688.65	
9	Net Profit Loss for the period from continuing operations	967.56	1809.25	
10	Profit (loss) from discontinuing operations before tax	0	0	
11	Tax expense of discontinuing operations	0	0	
12	Net profit (loss) from discontinuing operation after tax	0	0	
13	Profit (loss) for period before minority interest	967.56	1809.25	
14	Share of profit (loss) of associates			
15	Profit (loss) of minority interest			
16	Net profit (Loss) for the period	967.56	1809.25	
17	Details of equity share capital			
	Paid-up equity share capital	1193.3	1193.3	
	Face value of equity share capital	10	10	
	Details of debt securities			
18	Reserves excluding revaluation reserve		8342.52	
19	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	8.29	15.5	
	Diluted earnings (loss) per share from continuing and discontinued operations	8.29	15.5	
20	Debt equity ratio	0	0.08	Textual Information(1)

21	Debt service coverage ratio	0	73.29	Textual Information(2)
22	Interest service coverage ratio	0	44.68	Textual Information(3)
23	Disclosure of notes on financial results			

Statement of Asset and Liabilities		
	Particulars	Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	31-03-2026
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Standalone
	Equity and liabilities	
1	Shareholders' funds	
	Share capital	1193.3
	Reserves and surplus	8342.52
	Money received against share warrants	372.67
	Total shareholders' funds	9908.49
2	Share application money pending allotment	0
3	Deferred government grants	0
4	Minority interest	
5	Non-current liabilities	
	Long-term borrowings	670.98
	Deferred tax liabilities (net)	94.37
	Foreign currency monetary item translation difference liability account	0
	Other long-term liabilities	
1	Long-term Liabilities	7.02
2		
3		
4		
5		
	Details of other long-term liabilities	
	Total of other long-term liabilities	7.02
	Long-term provisions	0
	Total non-current liabilities	772.37
6	Current liabilities	
	Short-term borrowings	1788.47
	Trade Payables	
	(A) Total outstanding dues of micro enterprises and small enterprises	309.61
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	2293.31
	Total Trade payable	2602.92
	Other current liabilities	
1	Other Current Liabilities	278.87
2		
3		
4		
5		
	Details of other current liabilities	
	Total of other current liabilities	278.87
	Short-term provisions	567.93
	Total current liabilities	5238.19
	Total equity and liabilities	15919.05
	Assets	
1	Non-current assets	
(i)	Property, Plant and Equipment and Intangible assets	
	Property, Plant and Equipment	1826.55
	Producing properties	
	Intangible assets	1032.58
	Preproducing properties	
	Property, Plant and Equipment capital work-in-progress	

	Intangible assets under development or work-in-progress	
	Total Property, Plant and Equipment and Intangible assets	2859.13
(ii)	Non-current investments	1971.38
(v)	Deferred tax assets (net)	
(vi)	Foreign currency monetary item translation difference asset account	
(vii)	Long-term loans and advances	81.86
	Other non-current assets	
1	Other non-current assets	0.8
2		
3		
4		
5		
	Details of other non-current assets	
	Total of other non-current assets	0.8
	Total non-current assets	4913.17
2	Current assets	
	Current investments	2.15
	Inventories	2321.87
	Trade receivables	4934.11
	Cash and cash equivalents	406.64
	Bank balance other than cash and cash equivalents	0
	Short-term loans and advances	3094.41
	Other current assets	
1	Other Current Assets	246.7
2		
3		
4		
5		
	Details of other current assets	
	Total of other current assets	246.7
	Total current assets	11005.88
	Total assets	15919.05
	Disclosure of notes on assets and liabilities	Textual Information(1)

Text Block	
Textual Information(1)	

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results		
Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-10-2025	01-04-2025
Date of end of reporting period	31-03-2026	31-03-2026
Whether results are audited or unaudited	Audited	Audited
Nature of report standalone or consolidated	Standalone	Standalone
1 Segment Revenue		
(net sale/income from each segment should be disclosed)		
1		
Total segment revenue		
Less: Inter segment revenue		
Revenue from operations		
2 Segment Result		
Profit (+) / Loss (-) before tax and interest from each segment		
Total Profit before tax		
i. Finance cost		
ii. Other unallocable expenditure net off unallocable income		
Profit before tax		
3 (Segment Asset - Segment Liabilities)		
Segment Asset		
Total Segment Assets		
Un-allocable Assets		
Net Segment Assets		
4 Segment Liabilities		
Segment Liabilities		
Total Segment Liabilities		
Un-allocable Liabilities		
Net Segment Liabilities		

Cash flow statement - indirect	
Particulars	Year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2025
Date of end of reporting period	31-03-2026
Whether results are audited or unaudited	Audited
Nature of report standalone or consolidated	Standalone
1 Statement of cash flows	
Cash flows from used in operating activities	
Profit before extraordinary items and tax	2497.9
2 Adjustments for reconcile profit (loss)	
Adjustments to profit (loss)	
Adjustments for finance costs	166.25
Adjustments for depreciation and amortisation expense	185.93
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
Adjustments for unrealised foreign exchange losses gains	0
Adjustments for dividend income	0
Adjustments for share-based payments	0
Other adjustments for which cash effects are investing or financing cash flow	-229.38
Other adjustments to reconcile profit (loss)	0
Other adjustments for non-cash items	0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
Total adjustments to profit (loss)	122.8
3 Adjustments for working capital	
Adjustments for decrease (increase) in inventories	-664.63
Adjustments for decrease (increase) in trade receivables	-2893.95
Adjustments for decrease (increase) in other current assets	231.63
Adjustments for increase (decrease) in trade payables	1637.95
Adjustments for increase (decrease) in other current liabilities	197.29
Adjustments for provisions	303.46
Total adjustments for working capital	-1188.25
Total adjustments for reconcile profit (loss)	-1065.45
Net cash flows from (used in) operations	1432.45
Dividends received	0
Interest paid	0
Interest received	0
Income taxes paid (refund)	589.5
Other inflows (outflows) of cash	-49.76
Net cash flows from (used in) operating activities before extraordinary items	793.19
Proceeds from extraordinary items	0
Payment for extraordinary items	0
Net cash flows from (used in) operating activities	793.19
4 Cash flows from used in investing activities	
Cash flows from losing control of subsidiaries or other businesses	0
Cash flows used in obtaining control of subsidiaries or other businesses	0
Other cash receipts from sales of equity or debt instruments of other entities	-794.67
Other cash payments to acquire equity or debt instruments of other entities	0
Other cash receipts from sales of interests in joint ventures	0
Other cash payments to acquire interests in joint ventures	0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
Proceeds from sales of property plant and equipment	0
Purchase of property plant and equipment	1511.78
Proceeds from sales of intangible assets	0
Purchase of intangible assets	0

Cash advances and loans made to other parties	0
Cash receipts from repayment of advances and loans made to other parties	0
Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
Dividends received	0
Interest received	229.38
Income taxes paid (refund)	0
Other inflows (outflows) of cash	69.72
Proceeds from government grants	0
Net cash flows from (used in) investing activities before extraordinary items	-2007.35
Proceeds from extraordinary items	0
Payment for extraordinary items	0
Net cash flows from (used in) investing activities	-2007.35
5 Cash flows from used in financing activities	
Proceeds from issuing shares	1153.91
Proceeds from issuing other equity instruments	0
Proceeds from issuing debentures notes bonds etc	0
Proceeds from borrowings	31
Repayments of borrowings	0
Dividends paid	0
Interest paid	0
Income taxes paid (refund)	0
Other inflows (outflows) of cash	224.85
Net cash flows from (used in) financing activities before extraordinary items	1409.76
Proceeds from extraordinary items	0
Payment for extraordinary items	0
Net cash flows from (used in) financing activities	1409.76
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	195.6
6 Effect of exchange rate changes on cash and cash equivalents	
Effect of exchange rate changes on cash and cash equivalents	0
Net increase (decrease) in cash and cash equivalents	195.6
Cash and cash equivalents cash flow statement at beginning of period	211.02
Cash and cash equivalents cash flow statement at end of period	406.62

Format for Disclosure of Related Party Transactions (applicable only for I

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						
1	TRIDENT LIFELINE LIMITED	AAECT8906D	TNS PHARMA PRIVATE LIMITED	AAJCT0904G	SUBSIDIARY COMPANY	Sale of goods or services			as approved by Board and members		
2	TRIDENT LIFELINE LIMITED	AAECT8906D	TALON HEALTHCARE LLP	AAMFT9597P	DIRECTOR'S INTEREST	Sale of goods or services			as approved by Board and members		
3	TRIDENT LIFELINE LIMITED	AAECT8906D	TENCH LIFE SCIENCES LLP	AAMFT9299A	DIRECTOR'S INTEREST	Sale of goods or services			as approved by Board and members		
4	TRIDENT LIFELINE LIMITED	AAECT8906D	TNS PHARMA PRIVATE LIMITED	AAJCT0904G	SUBSIDIARY COMPANY	Purchase of goods or services			as approved by Board and members		
5	TRIDENT LIFELINE LIMITED	AAECT8906D	TRIDENT MEDIQUIP LIMITED	AAHCT5650R	SUBSIDIARY COMPANY	Interest received			as approved by Board and members		
6	TRIDENT LIFELINE LIMITED	AAECT8906D	TNS PHARMA PRIVATE LIMITED	AAJCT0904G	SUBSIDIARY COMPANY	Interest received			as approved by Board and members		
7	TRIDENT LIFELINE LIMITED	AAECT8906D	TENCH LIFE SCIENCES LLP	AAMFT9299A	DIRECTOR'S INTEREST	Interest received			as approved by Board and members		
8	TRIDENT LIFELINE LIMITED	AAECT8906D	TALON HEALTHCARE LLP	AAMFT9597P	DIRECTOR'S INTEREST	Interest received			as approved by Board and members		
9	TRIDENT LIFELINE LIMITED	AAECT8906D	TLL WELLNESS LIMITED	AAHCT6372N	DIRECTOR'S INTEREST	Interest received			as approved by Board and members		
10	TRIDENT LIFELINE LIMITED	AAECT8906D	TLL INDUSTRIES LIMITED	AAKCT0602Q	DIRECTOR'S INTEREST	Interest received			as approved by Board and members		
11	TRIDENT LIFELINE LIMITED	AAECT8906D	TLL ELEMENTS PRIVATE LIMITED	AAKCT9256C	SUBSIDIARY COMPANY	Interest received			as approved by Board and members		
12	TRIDENT LIFELINE LIMITED	AAECT8906D	TLL PARENTERALS LIMITED	AAKCT6315Q	SUBSIDIARY COMPANY	Interest received			as approved by Board and members		
13	TRIDENT LIFELINE LIMITED	AAECT8906D	TRIDENT TEXOFAB LIMITED	AADCT0381R	DIRECTOR'S INTEREST	Interest received			as approved by Board		

									and members		
14	TRIDENT LIFELINE LIMITED	AAECT8906D	VN CAPITAL SERVICES LLP	AAOFV5800F	DIRECTOR'S INTEREST	Interest received			as approved by Board and members		
15	TRIDENT LIFELINE LIMITED	AAECT8906D	TRIDENT MEDIQUIP LIMITED	AAHCT5650R	SUBSIDIARY COMPANY	Loan			as approved by Board and members		
16	TRIDENT LIFELINE LIMITED	AAECT8906D	TNS PHARMA PRIVATE LIMITED	AAJCT0904G	SUBSIDIARY COMPANY	Loan			as approved by Board and members		
17	TRIDENT LIFELINE LIMITED	AAECT8906D	TALON HEALTHCARE LLP	AAMFT9597P	DIRECTOR'S INTEREST	Loan			as approved by Board and members		
18	TRIDENT LIFELINE LIMITED	AAECT8906D	TENCH LIFE SCIENCES LLP	AAMFT9299A	DIRECTOR'S INTEREST	Loan			as approved by Board and members		
19	TRIDENT LIFELINE LIMITED	AAECT8906D	TLL ELEMENTS PRIVATE LIMITED	AAKCT9256C	SUBSIDIARY COMPANY	Loan			as approved by Board and members		
20	TRIDENT LIFELINE LIMITED	AAECT8906D	TLL WELLNESS LIMITED	AAHCT6372N	SUBSIDIARY COMPANY	Loan			as approved by Board and members		
21	TRIDENT LIFELINE LIMITED	AAECT8906D	TLL PARENTERALS LIMITED	AAKCT6315Q	SUBSIDIARY COMPANY	Loan			as approved by Board and members		
22	TRIDENT LIFELINE LIMITED	AAECT8906D	TLL INDUSTRIES LIMITED	AAKCT0602Q	DIRECTOR'S INTEREST	Loan			as approved by Board and members		
23	TRIDENT LIFELINE LIMITED	AAECT8906D	TLL LABORATORIES PRIVATE LIMITED	AAJCT4459J	DIRECTOR'S INTEREST	Loan			as approved by Board and members		
24	TRIDENT LIFELINE LIMITED	AAECT8906D	TRIDENT TEXOFAB LIMITED	AADCT0381R	DIRECTOR'S INTEREST	Loan			as approved by Board and members		
25	TRIDENT LIFELINE LIMITED	AAECT8906D	VN CAPITAL SERVICES LLP	AAOFV5800F	DIRECTOR'S INTEREST	Loan			as approved by Board and members		
26	TRIDENT LIFELINE LIMITED	AAECT8906D	HARDIK JIGISHKUMAR DESAI	AAKPD1044M	DIRECTOR	Remuneration			as approved by Board and members		
27	TRIDENT LIFELINE LIMITED	AAECT8906D	MANIYA HARDIK DESAI	AKLPA5041J	DIRECTOR	Remuneration			as approved by Board and members		
28	TRIDENT LIFELINE LIMITED	AAECT8906D	SHRAVAN H PATEL	BZEPP9973M	DIRECTOR	Remuneration			as approved by Board and members		
29	TRIDENT LIFELINE LIMITED	AAECT8906D	RUPABEN CHETAN JARIWALA	AJBPJ5208K	DIRECTOR	Remuneration			as approved by Board and members		
30	TRIDENT LIFELINE LIMITED	AAECT8906D	ASHISH ANANDSINGH BAFNA	ADSPB6657R	DIRECTOR	Remuneration			as approved by Board		

									and members		
31	TRIDENT LIFELINE LIMITED	AAECT8906D	HARDIK DESAI FAMILY TRUST	AACTH5581P	DIRECTOR INTEREST	Interest paid			as approved by Board and members		
32	TRIDENT LIFELINE LIMITED	AAECT8906D	MANIYA HARDIK DESAI	AKLPA5041J	DIRECTOR	Interest paid			as approved by Board and members		
33	TRIDENT LIFELINE LIMITED	AAECT8906D	HARDIK JIGISHKUMAR DESAI	AAKPD1044M	DIRECTOR	Interest paid			as approved by Board and members		
34	TRIDENT LIFELINE LIMITED	AAECT8906D	MISHAL SHAILESH PATEL	ATNPP1675Q	INDEPENDENT DIRECTOR	Any other transaction	SITTING FEES		as approved by Board and members		
35	TRIDENT LIFELINE LIMITED	AAECT8906D	FALGUNI BHAVESH JARIWALA	ADVPJ7810P	INDEPENDENT DIRECTOR	Any other transaction	SITTING FEES		as approved by Board and members		
36	TRIDENT LIFELINE LIMITED	AAECT8906D	HARDIK JIGISHKUMAR DESAI	AAKPD1044M	DIRECTOR	Loan			as approved by Board and members		
Total value of transaction during the reporting period											

Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	A BAFNA & ASSOCIATES	Yes	30-04-2027

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)	
Mode of Fund Raising	Public Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	04-10-2022
Amount Raised	3534.19
Report filed for Quarter ended	31-03-2026
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	
Comments of the Audit Committee after review	NA
Comments of the auditors, if any	NA

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	To Meet working capital requirement	NA	2050	0	2035.65	0	
2	Product registration in the international Market	NA	513.66	0	75.81	0	
3	General Corporate Purpose	NA	670.53	0	670.49	0	
4	Public Issue Expense	NA	300	0	300	0	

Signatory Details	
Name of signatory	NIKITA SHARMA
Designation of person	Company Secretary and Compliance Officer
Place	SURAT
Date	07-05-2026

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	09-06-2025
Amount Raised	2657.34
Report filed for Quarter ended	31-03-2026
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	
Comments of the Audit Committee after review	NA
Comments of the auditors, if any	NA

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	To Meet working capital requirements, to make investment in Subsidiary/associates/Joint Ventures and to meet their working capital requirement, repayment of Secured Borrowing of the Company, Business Expansion and other genral corporate purpose	NA	2657.34	0	1526.57	0	

